SAN DIEGO & SEATTLE--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juno Therapeutics, Inc. (NASDAQGS: JUNO) breached their fiduciary duty to shareholders by engaging in self-dealing and issuing materially false and misleading statements regarding the side effects of its lead product candidate, JCAR015.
View this press release on the firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/juno-therapeutics-inc-september-2017
Investors Survive Defendants' Motion to Dismiss in Securities Class Action
Juno is currently the subject of a federal securities class action alleging that between June 4, 2016 and November 22, 2016, Juno officials understated the risks associated with JCAR015. In July 2016, in addition to finally disclosing several patient deaths associated with the drug, Juno revealed that the FDA issued a clinical hold. On June 14, 2017, U.S. District Judge Ricardo Martinez issued an order in the securities class action denying defendants' motion to dismiss.
Juno Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
